Elan Sues Over Biogen Objection To $1B J&J Deal
Elan Corp. PLC went on the offensive Thursday against Biogen Idec Inc., its partner in developing the multiple sclerosis treatment Tysabri, to secure a court order that a $1 billion acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article